

Emmanouil Fokas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7947817/publications.pdf>

Version: 2024-02-01

103
papers

4,757
citations

94269

37
h-index

106150

65
g-index

113
all docs

113
docs citations

113
times ranked

7763
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 354-360.	1.0	0
2	The radiotherapy quality assurance gap among phase III cancer clinical trials. <i>Radiotherapy and Oncology</i> , 2022, 166, 51-57.	0.3	11
3	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2022, 8, e215445.	3.4	127
4	Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis. <i>Cancer Research</i> , 2022, 82, 1380-1395.	0.4	10
5	Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. <i>Cancer Cell</i> , 2022, 40, 168-184.e13.	7.7	117
6	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. <i>Neurology</i> , 2022, 98, .	1.5	2
7	C-Reactive Protein to Albumin Ratio as Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy. <i>Biomedicines</i> , 2022, 10, 598.	1.4	10
8	Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. <i>European Radiology</i> , 2022, 32, 4991-5003.	2.3	32
9	Do We Have Enough Evidence to Propose a Preferred Total Neoadjuvant Therapy Sequence for Patients With Locally Advanced Rectal Cancer?â€”Reply. <i>JAMA Oncology</i> , 2022, , .	3.4	0
10	ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 99-106.	0.9	7
11	Compliance to chemoradiation in squamous cell carcinoma of the anus. <i>Cancer Treatment Reviews</i> , 2022, 106, 102381.	3.4	1
12	Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 654-662.	1.0	10
13	Advances in nanotechnology-based platforms for survivin-targeted drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 733-754.	2.5	10
14	A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2373-2383.	1.2	2
15	Single-shot bevacizumab for cerebral radiation injury. <i>BMC Neurology</i> , 2021, 21, 77.	0.8	8
16	Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancerâ€”A Promising Signaling Network for Therapeutic Interventions. <i>Cancers</i> , 2021, 13, 624.	1.7	17
17	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	12.5	93
18	Innovative radiation oncology Togetherâ€”Precise,â€”Personalized,â€”Human. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1043-1048.	1.0	7

#	ARTICLE	IF	CITATIONS
19	A Spatial and Functional Interaction of a Heterotetramer Survivin-DNA-PKcs Complex in DNA Damage Response. <i>Cancer Research</i> , 2021, 81, 2304-2317.	0.4	8
20	Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2021, 164, 223-231.	0.3	8
21	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. <i>Cancers</i> , 2021, 13, 5748.	1.7	11
22	Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial. <i>Cancers</i> , 2020, 12, 3549.	1.7	9
23	Sarcopenia Is Associated With Hematologic Toxicity During Chemoradiotherapy in Patients With Anal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1576.	1.3	5
24	RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 43-49.	0.9	16
25	Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1. <i>Cells</i> , 2020, 9, 1235.	1.8	5
26	Management of anal cancer patients - a pattern of care analysis in German-speaking countries. <i>Radiation Oncology</i> , 2020, 15, 122.	1.2	5
27	ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 987-995.	0.4	46
28	Outcome measures in multimodal rectal cancer trials. <i>Lancet Oncology</i> , The, 2020, 21, e252-e264.	5.1	56
29	Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. <i>Radiotherapy and Oncology</i> , 2020, 149, 168-173.	0.3	4
30	Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy. <i>Frontiers in Oncology</i> , 2019, 9, 742.	1.3	5
31	Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. <i>Journal of Clinical Oncology</i> , 2019, 37, 3212-3222.	0.8	333
32	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. <i>Cancers</i> , 2019, 11, 472.	1.7	24
33	Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 20.	1.3	18
34	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 126-137.	3.3	12
35	Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients. <i>Journal of Neuro-Oncology</i> , 2019, 142, 161-169.	1.4	9
36	Anal squamous cell carcinoma - State of the art management and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 65, 11-21.	3.4	37

#	ARTICLE	IF	CITATIONS
37	Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 214-221.	0.3	7
38	Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. <i>Annals of Oncology</i> , 2018, 29, 1521-1527.	0.6	61
39	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	2.3	50
40	Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials. <i>Radiotherapy and Oncology</i> , 2018, 128, 557-563.	0.3	7
41	Radiation Therapy in Rectal Cancer. , 2018, , 1-21.		0
42	Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer. <i>JAMA Surgery</i> , 2018, 153, e181607.	2.2	77
43	Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 305-314.	1.0	7
44	Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis. <i>British Journal of Cancer</i> , 2017, 116, 1350-1357.	2.9	78
45	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2017, 141, 594-603.	2.3	91
46	The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 221-230.	3.3	23
47	Human papilloma virus load and PD-1/PD-L1, CD8 ⁺ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. <i>OncImmunity</i> , 2017, 6, e1288331.	2.1	79
48	PD-1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. <i>EMBO Molecular Medicine</i> , 2017, 9, 167-180.	3.3	172
49	Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. <i>Oncology Letters</i> , 2017, 14, 1141-1146.	0.8	58
50	Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. <i>Cancer Research</i> , 2017, 77, 5952-5962.	0.4	50
51	Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	105
52	Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using ¹¹¹ In-bevacizumab. <i>EJNMMI Research</i> , 2017, 7, 49.	1.1	3
53	Complete response after chemoradiotherapy for rectal cancer: what is the reasonable approach?. <i>Innovative Surgical Sciences</i> , 2017, 3, 47-53.	0.4	0
54	Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8 ⁺ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1225.	2.2	29

#	ARTICLE	IF	CITATIONS
55	An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouse. <i>PLoS ONE</i> , 2017, 12, e0176693.	1.1	12
56	Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. <i>Oncotarget</i> , 2017, 8, 4668-4689.	0.8	74
57	Situation of young radiation oncologists, medical physicists and radiation biologists in German-speaking countries. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 507-515.	1.0	9
58	Targeted agents in GI radiotherapy: Clinical efficacy and side effects. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 537-549.	1.0	5
59	ARCI: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 306-311.	0.3	43
60	Rectal cancer: Neoadjuvant chemoradiotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 629-639.	1.0	49
61	Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial. <i>Radiotherapy and Oncology</i> , 2016, 120, 212-216.	0.3	23
62	The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. <i>Nature Communications</i> , 2016, 7, 12308.	5.8	173
63	A phase-I trial of preoperative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the SPARC™ trial protocol. <i>BMC Cancer</i> , 2016, 16, 728.	1.1	13
64	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). <i>International Journal of Cancer</i> , 2016, 138, 171-181.	2.3	184
65	Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. <i>Oncotarget</i> , 2016, 7, 53339-53349.	0.8	12
66	Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 72819-72832.	0.8	16
67	Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. <i>Oncotarget</i> , 2016, 7, 76613-76627.	0.8	27
68	The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 4183-4194.	0.8	91
69	Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. <i>Visceral Medicine</i> , 2015, 31, 347-353.	0.5	8
70	Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. <i>Radiotherapy and Oncology</i> , 2015, 117, 432-437.	0.3	22
71	Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: The reverse of the Will Rogers phenomenon?. <i>Cancer</i> , 2015, 121, 1724-1727.	2.0	23
72	Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 61-82.	3.3	46

#	ARTICLE	IF	CITATIONS
73	Human papillomavirus DNA load and p16 ^{INK4a} expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. <i>International Journal of Cancer</i> , 2015, 136, 278-288.	2.3	75
74	miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). <i>Oncotarget</i> , 2015, 6, 22439-22451.	0.8	29
75	Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. <i>OncoImmunology</i> , 2014, 3, e27403.	2.1	61
76	In Reply to Weiss et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1259-1260.	0.4	0
77	Regulation of O ₂ consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. <i>Radiotherapy and Oncology</i> , 2014, 111, 72-80.	0.3	37
78	Stereotactic Radiation Therapy for Benign Meningioma: Long-Term Outcome in 318 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 569-575.	0.4	57
79	Stereotactic radiotherapy of benign meningioma in the elderly: Clinical outcome and toxicity in 121 patients. <i>Radiotherapy and Oncology</i> , 2014, 111, 457-462.	0.3	25
80	Targeting ATR in DNA damage response and cancer therapeutics. <i>Cancer Treatment Reviews</i> , 2014, 40, 109-117.	3.4	152
81	Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1554-1562.	0.8	351
82	Quality of life after stereotactic radiotherapy for meningioma: a prospective non-randomized study. <i>Journal of Neuro-Oncology</i> , 2013, 113, 135-141.	1.4	24
83	A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 107, 200-206.	0.3	13
84	Stereotactic radiosurgery of cerebral arteriovenous malformations: long-term follow-up in 164 patients of a single institution. <i>Journal of Neurology</i> , 2013, 260, 2156-2162.	1.8	48
85	Preoperative Chemoradiation Therapy With Capecitabine/Oxaliplatin and Cetuximab in Rectal Cancer: Long-Term Results of a Prospective Phase 1/2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 992-999.	0.4	19
86	Biology of brain metastases and novel targeted therapies: Time to translate the research. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 61-75.	3.3	37
87	The Role of Radiotherapy in the Multimodal Management of Esophageal Cancer. <i>Digestive Diseases</i> , 2013, 31, 30-37.	0.8	18
88	Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiotherapy treatment plans for locally-advanced pancreatic cancer. <i>Acta Oncologica</i> , 2013, 52, 1573-1578.	0.8	6
89	Dual Inhibition of the PI3K/mTOR Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature. <i>Cancer Research</i> , 2012, 72, 239-248.	0.4	121
90	Brain Metastases in Breast Cancer: Analysis of the Role of HER2 Status and Treatment in the Outcome of 94 Patients. <i>Tumori</i> , 2012, 98, 768-774.	0.6	10

#	ARTICLE	IF	CITATIONS
91	The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 823-842.	2.7	59
92	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. <i>Radiation Oncology</i> , 2012, 7, 48.	1.2	73
93	The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. <i>Cancer Biology and Therapy</i> , 2012, 13, 1072-1081.	1.5	205
94	Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. <i>Journal of Neuro-Oncology</i> , 2012, 109, 91-98.	1.4	103
95	Brain metastases in breast cancer: analysis of the role of HER2 status and treatment in the outcome of 94 patients. <i>Tumori</i> , 2012, 98, 768-74.	0.6	8
96	Multidisciplinary Treatment of Brain Metastases Derived From Colorectal Cancer Incorporating Stereotactic Radiosurgery: Analysis of 78 Patients. <i>Clinical Colorectal Cancer</i> , 2011, 10, 121-125.	1.0	26
97	Delta-Like Ligand 4 Notch Blockade and Tumor Radiation Response. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1778-1798.	3.0	57
98	Radiotherapy for Brain Metastases from Renal Cell Cancer: Should Whole-Brain Radiotherapy Be Added to Stereotactic Radiosurgery?. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 210-217.	1.0	77
99	A Comparison of Radiotherapy with Radiotherapy plus Surgery for Brain Metastases from Urinary Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 565-571.	1.0	27
100	Irradiation-Dependent Effects on Tumor Perfusion and Endogenous and Exogenous Hypoxia Markers in an A549 Xenograft Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1500-1508.	0.4	16
101	EphA2 blockade enhances the anti-endothelial effect of radiation and inhibits irradiated tumor cell-induced migration of endothelial cells. <i>Thoracic Cancer</i> , 2010, 1, 153-162.	0.8	11
102	Hypofractionated Stereotactic Reirradiation of Recurrent Glioblastomas. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 235-240.	1.0	136
103	Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 0, 7, 40992-41004.	0.8	69